全球大麻二酚 (CBD) 檢測市場規模、份額和趨勢分析報告—產業概覽及 2032 年預測

大麻二酚（CBD）測試市場規模

• 2024 年全球大麻二酚 (CBD) 測試市場規模為508.5 億美元 ，預計 到 2032 年將達到 740 億美元，預測期內 複合年增長率為 4.80%。
• 市場成長主要得益於各國大麻合法化程度的提高、對 CBD 產品的需求不斷增長以及確保產品品質和安全的嚴格監管要求
• 高效液相層析法 (HPLC) 和氣相層析質譜法 (GC-MS) 等測試技術的進步，透過實現精確的大麻素分析和污染檢測，進一步促進了市場擴張

大麻二酚（CBD）檢測市場分析

• CBD 在食品、飲料、製藥和化妝品行業日益普及，推動了對可靠、準確的測試解決方案的需求
• 市場參與者正專注於先進的色譜技術並擴大測試實驗室的能力，以滿足合規標準和不斷增長的商業需求
• 北美在大麻二酚 (CBD) 測試市場佔據主導地位，2024 年其收入份額最大，為 41.56%，這得益於有利的監管發展、醫用和娛樂用大麻的日益合法化以及對產品標準化日益增長的需求
• 亞太地區預計將成為全球大麻二酚 (CBD) 測試市場增長率最高的地區，這得益於大麻產品合法化的不斷擴大、產品安全意識的不斷增強以及中國、日本和澳大利亞等國家對測試基礎設施的投資不斷增加。
• 分析儀器領域在2024年佔據了最大的收入份額，這得益於在受監管環境下進行精確和高通量測試的需求不斷增長。高效液相層析（HPLC）、氣相層析-質譜聯用（GC-MS）和光譜系統等儀器越來越多地用於精確的CBD含量定量和污染物檢測。隨著各國監管標準的收緊，檢測實驗室正在大力投資先進的分析設備，以確保合規性和產品安全。

報告範圍和大麻二酚（CBD）測試市場細分 

大麻二酚（CBD）檢測市場趨勢

“整合先進色譜技術，實現高精度測試”

• CBD 產品的日益複雜化促使實驗室採用先進的色譜方法，例如高效液相層析法 (HPLC) 和氣相層析質譜法 (GC-MS) 進行精確分析
• 這些技術不僅有助於識別大麻二酚含量，還能辨識微量的四氫大麻酚、萜烯、殘留溶劑和重金屬，以確保消費者安全和法律合規
• 製藥公司對臨床級測試的需求不斷增長，加速了向經過驗證和可重複的測試方案的轉變
• 隨著競爭加劇，品牌正在利用第三方實驗室認證來增強產品可信度，並在飽和的市場中脫穎而出
• 採用自動化和數據整合色譜系統也提高了測試吞吐量並縮短了周轉時間
  • For instance, Eurofins Scientific has expanded its CBD testing capabilities in the U.S. using LC-MS and GC-MS technologies to provide full-spectrum analysis for edible, topical, and oil-based CBD products.

Cannabidiol (CBD) Testing Market Dynamics

Driver

“Growing Regulatory Support and Legalization of CBD Products”

• Global regulatory shifts supporting medical and recreational cannabis use have catalyzed the demand for safety-focused CBD testing services
• In countries such as Canada, the U.S., and parts of the EU, testing is legally required for product potency, purity, and contaminant levels before retail distribution
• Government agencies are actively funding research into cannabinoid safety, fostering innovation in lab testing protocols and infrastructure
• Legal clarity is encouraging small and mid-sized labs to enter the CBD testing space, driving availability and affordability of certified analysis
• Increased consumer awareness around health risks from mislabeled or contaminated CBD products is also pushing manufacturers to opt for comprehensive third-party testing
  • For instance, California’s Department of Cannabis Control requires all CBD products sold within the state to pass stringent lab testing for residual solvents, microbial impurities, and potency — a mandate that has led to a boom in licensed testing facilities.

Restraint/Challenge

“Lack of Standardization in Testing Protocols across Regions”

• Despite global growth, no universal standard exists for CBD testing, resulting in fragmented compliance frameworks across North America, Europe, and Asia-Pacific
• Labs in different regions use varying reference standards, extraction methods, and analytical instruments, often leading to inconsistent test results for the same product
• Manufacturers aiming for international expansion must retest their products according to each region’s local guidelines, increasing time and cost burdens
• Disparities in THC threshold limits (e.g., 0.3% in the U.S. vs. 0.2% in the EU) create compliance challenges, especially for full-spectrum CBD oils
• The absence of globally recognized accreditation for cannabis testing labs further complicates consumer trust and cross-border product standardization
  • For instance, a U.S.-based CBD company exporting to Germany had to reformulate its entire product line after German authorities rejected their original batch for exceeding local THC content, despite being compliant in the U.S.

Cannabidiol (CBD) Testing Market Scope

The market is segmented on the basis of product and software, testing procedures, and end-user.

• By Product and Software

On the basis of product and software, the cannabidiol (CBD) testing market is segmented into analytical instruments, consumables, and software. The analytical instruments segment accounted for the largest revenue share in 2024, driven by growing demand for accurate and high-throughput testing in regulated environments. Instruments such as HPLC, GC-MS, and spectroscopy systems are increasingly used for precise CBD content quantification and contaminant detection. As regulatory standards tighten across various countries, testing labs are investing heavily in sophisticated analytical equipment to ensure compliance and product safety.

The software segment is expected to witness the fastest growth rate from 2025 to 2032, owing to the rising need for automation, data management, and regulatory traceability. Integrated laboratory information management systems (LIMS) streamline workflow, reporting, and compliance, especially in multi-location testing labs and research facilities.

• By Testing Procedures

On the basis of testing procedures, the market is segmented into residual solvent screening, terpene profiling, potency testing, genetic testing, pesticide screening, heavy metal testing, and microbial analysis. Potency testing dominated the market in 2024 with the largest share, driven by the requirement to accurately label CBD concentration in consumer products. Regulatory authorities across North America and Europe mandate precise potency testing to protect public health and ensure truthful product claims.

Microbial analysis is expected to witness the fastest growth rate from 2025 to 2032, propelled by rising concerns around contamination in edibles and topicals. Pathogen detection—including E. coli and Salmonella—is critical in maintaining consumer safety and quality assurance. An instance of this was seen in California, where microbial contamination prompted the recall of several CBD-infused consumables in 2023.

• By End-User

On the basis of end-user, the CBD testing market is segmented into laboratories, cannabis cultivators, research institutes, drug manufacturers, and dispensaries. The laboratories segment held the largest revenue share in 2024, driven by the increasing number of third-party testing facilities that cater to cannabis brands and cultivators seeking regulatory certification and product validation. These labs are central to maintaining trust in the CBD supply chain.

Drug manufacturers is expected to witness the fastest growth rate from 2025 to 2032, supported by expanding R&D investments in cannabidiol-based pharmaceuticals. With rising interest in CBD as a therapeutic agent for anxiety, epilepsy, and pain management, manufacturers are implementing rigorous testing protocols to meet FDA and EMA standards.

Cannabidiol (CBD) Testing Market Regional Analysis

• 受有利的監管發展、醫用和娛樂用大麻合法化程度的提高以及產品標準化需求的不斷增長的推動，北美在 2024 年佔據了大麻二酚 (CBD) 測試市場的主導地位，收入份額最高，為 41.56%

• 該地區的消費者和企業高度重視產品的安全性、功效和透明度，這增加了對先進測試程序的需求

• 第三方實驗室測試、政府合規標準以及完善的實驗室網路的廣泛採用進一步支持了北美在市場上的領導地位

美國大麻二酚（CBD）檢測市場洞察

2024年，美國CBD檢測市場佔據了北美大部分市場份額，這得益於CBD產品消費量的不斷增長以及由FDA等機構主導的嚴格監管框架。隨著大麻衍生的健康和治療產品在市場上的激增，製造商被迫確保其純度、效力和安全標準。對經過實驗室測試的CBD油、酊劑和食用產品的需求日益增長，尤其是在註重健康的消費者群體中，這推動了市場的成長。獨立檢測實驗室的擴張以及各州品質標準的實施也顯著促進了美國市場的擴張。

歐洲大麻二酚（CBD）檢測市場洞察

預計歐洲CBD檢測市場將在2025年至2032年間實現最快成長，這得益於市場對高品質大麻保健產品日益增長的需求，以及歐盟法規協調一致的推動。德國和荷蘭等國的監管機構正在強調產品檢測，以確保消費者安全和產品真實性。此外，歐洲消費者對CBD藥用益處的認識不斷提高，也促使人們採取負責任的採購和實驗室驗證措施。歐洲充滿活力的監管格局以及專門的大麻研究機構的存在，有助於該地區建立強大的檢測基礎設施。

英國大麻二酚（CBD）檢測市場洞察

英國CBD檢測市場預計將在2025年至2032年間迎來最快增長，這得益於英國食品標準局（FSA）的監管舉措以及消費者對安全認證CBD產品日益增長的需求。企業需要提交包含詳細產品檢測數據的新型食品申請，加速了對檢測服務的投資。此外，含CBD的保養品和保健產品日益普及，也加劇了對嚴格的微生物、農藥和重金屬篩檢的需求，以滿足市場預期。

德國大麻二酚（CBD）檢測市場洞察

由於政府對醫用大麻的積極態度以及對大麻研發的持續投入，預計德國CBD檢測市場將在2025年至2032年間實現最快成長。德國對藥品級品質的要求和管制物質法規要求在整個供應鏈中實施全面的檢測程序。國內生產商和國際供應商都必須遵守嚴格的效力和污染標準，並鼓勵與認證的實驗室建立合作關係。德國在歐洲大麻生態系統中的核心地位進一步推動了分析檢測服務的成長。

亞太地區大麻二酚（CBD）檢測市場洞察

預計亞太地區CBD檢測市場將在2025年至2032年間實現最快成長，這得益於CBD產品的逐步合法化，以及中國、印度和泰國等新興經濟體對大麻衍生藥物日益增長的興趣。該地區各國政府正在探索大麻種植的經濟效益，同時實施嚴格的品質控制措施，從而推動了對可靠檢測基礎設施的需求。越來越多的研究合作，加上公共衛生舉措，也正在提升檢測能力，促進CBD的安全消費。

日本大麻二酚（CBD）檢測市場洞察

由於法規不斷完善、健康意識不斷提升以及日本嚴格的品質控制標準，預計日本CBD檢測市場將在2025年至2032年間實現最快成長。儘管大麻仍受到嚴格監管，但市場對CBD化妝品和保健品的需求正推動著合規檢測服務的投資。日本消費市場注重安全性和產品完整性，促使零售商與認證實驗室合作，進行萜烯分析和效力驗證。這些趨勢預計將鞏固日本在高端CBD領域的地位。

中國大麻二酚（CBD）檢測市場洞察

2024年，中國CBD檢測市場佔據亞太地區最大份額，這得益於中國在工業大麻種植領域的主導地位以及CBD產品出口的不斷增長。儘管國內消費受到嚴格監管，但對經過測試且符合出口要求的CBD油、化妝品和原材料的需求，正在顯著推動檢測服務的發展。由於主要的製造中心位於雲南和黑龍江等省份，先進的分析儀器和標準化的實驗室流程的整合對於進入全球市場至關重要。

大麻二酚（CBD）檢測市場份額

大麻二酚（CBD）測試產業主要由知名公司主導，包括：

• CannaSafe（美國）
• Steep Hill, Inc（美國）
• Eirlab 研究小組（愛爾蘭）
• GOODBODY HEALTH INC.（美國）
• CW ANALYTICAL（美國）
• Pure Analytics（美國）
• ANRESCO（美國）
• SC Labs（印度）
• 巴特爾紀念研究所（美國）
• Aphria Inc (Canada)
• Medical Marijuana, Inc (U.S.)
• STENOCARE A/S (Denmark)
• Cannabis Science Inc (U.S.)
• Agilent Technologies, Inc. (U.S.)

Latest Developments in Global Cannabidiol (CBD) Testing Market

• In July 2020, Agilent Technologies recently unveiled pioneering solutions for the surging Global Cannabidiol (CBD) Testing Market, addressing challenges in potency and pesticide/mycotoxin assessments for cannabis and hemp. Launching the Agilent eMethods tool and two kits—Cannabis and Hemp Potency, and Cannabis Pesticide and Mycotoxin—the brand offers a swift setup with step-by-step instructions and consumables for comprehensive analysis. This innovative approach streamlines lab operations, aiding compliance with varying regulations. Monty Benefiel and Angelica Riemann, Agilent VPs, emphasized these solutions' role in establishing efficient testing procedures, enhancing productivity, and minimizing risks

SKU-57432